Nerviano Medical Sciences

The largest pharmaceutical R&D facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe.
Vinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo Slider

Latest News

Ignyta and Nerviano Announce License Agreement for Two First-in-Class Kinase Inhibitors August 4, 2014 - San Diego, CA, USA & Nerviano, Italy --(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, and Nerviano Medical Sciences, S.r.l., a leading oncology discovery organization, today announced that they have signed a license agreement that grants Ignyta exclusive global development and commercialization rights to two new drug... Read more
Cellectis and Accelera (Nerviano Medical Sciences Group) sign an agreement to complete preclinical studies of Cellectis lead product candidate UCART19 June 5, 2014 – Milan (Italy) and Paris (France) – Cellectis (Alternext: ALCLS.PA), a leader of allogeneic CAR T-cell therapies, and Accelera, the preclinical CRO (Contract Research Organisation) within the Nerviano Medical Sciences Group, recently signed an agreement to complete the preclinical studies of Cellectis’ advanced product candidate, UCART19. Engineered allogeneic CD19 T-cells... Read more
Phase I data of RXDX-101, a kinase inhibitor discovered at Nerviano Medical Sciences, in patients with advanced solid tumors with relevant molecular alterations to be disclosed at 2014 ASCO Nerviano, Italy, May 14, 2014 – Nerviano Medical Sciences has discovered RXDX-101, an oral pan-trk, ROS1, and ALK inhibitor, recently outlicenced to Ignyta, Inc, San Diego, CA.Phase I results of RXDX-101 in patients with advanced solid tumors with relevant molecular alterations will be disclosed at the 2014 American Society of Clinical Oncology (ASCO) annual meeting. Read more

Oncology

Nerviano Medical SciencesWe fight cancer. Our mission is to identify innovative agents for clinical development in areas of unmet

Read more...

CLIOSS

Nerviano Medical SciencesCLIOSS operates as your partner in the clinical development and life-cycle management

Read more...

Accelera

AcceleraAccelera is committed to predicting and managing potential toxic, pharmacokinetic

Read more...

NerPharMa

NerpharmaNerPharMa is a leading player in high-containment contract

Read more...